Diversified PET/MR differentiates more breast lesions

Using a multiparametric (MP) approach, PET/MR imaging with F-18 FDG, dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI) and 3-D proton MR spectroscopic imaging (3D H-MRSI) is superior for telling apart different kinds of breast tumors, according to a study published online June 24 in Clinical Cancer Research.

Thomas H. Helbich, MD, from the department of biomedical imaging and image-guided therapy in the division of molecular and gender imaging at the Medical University of Vienna, Austria, and colleagues assessed the four-part PET/MR scan in the study of 75 female patients with a spectrum of 53 malignant and 23 benign breast lesions. They found that having multiple parameters improved detection of both malignant and benign tumors.

This MP-PET/MR approach was 96 percent accurate for differentiating benign and malignant growths and using two or three parameters was determined to be the best practice. Compared to DCE-MRI alone, using this MP technique could cut down on as much as 50 percent of unnecessary breast biopsies.

“This feasibility study shows that MP F-18 FDG PET-MRI enables an improved differentiation of benign and malignant breast tumors when several MRI and PET parameters are combined. MP F-18 FDG PET-MRI may lead to a reduction in unnecessary breast biopsies,” concluded the authors.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.